tiprankstipranks
Nuvation Bio (NUVB)
NYSE:NUVB
US Market

Nuvation Bio (NUVB) Income Statement

106 Followers

Nuvation Bio Income Statement

Last quarter (Q4 2023), Nuvation Bio's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Nuvation Bio's net income was $-16.02M. See Nuvation Bio’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
----$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 46.78M$ 99.82M$ -119.73M$ -93.32M$ 43.82M
Operating Income
$ -100.28M$ -99.82M$ -120.61M$ -93.96M$ -43.82M
Net Non Operating Interest Income Expense
$ 24.61M$ 24.61M$ 7.45M$ 2.96M$ 1.95M
Other Income Expense
$ -6.07M$ -6.07M$ -4.62M$ -4.31M$ 218.00K
Pretax Income
$ -75.80M$ -75.80M$ -104.20M$ -86.85M$ -41.66M
Tax Provision
--$ -2.00K$ -1.00K$ 0.00
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -74.34M$ -75.80M$ -108.54M$ -86.69M$ -41.66M
Basic EPS
$ -63.24$ -0.35$ -0.48-$ -0.19
Diluted EPS
$ -63.24$ -0.35$ -0.48$ -0.44$ -0.19
Basic Average Shares
$ 875.52K$ 218.88K$ 216.72K$ 197.89M$ 217.65M
Diluted Average Shares
$ 875.52K$ 218.88K$ 216.72K-$ 217.65M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 46.78M$ 99.82M$ -119.73M$ -93.32M$ 43.82M
Net Income From Continuing And Discontinued Operation
$ -75.80M$ -75.80M$ -108.54M$ -86.69M$ -41.66M
Normalized Income
$ -42.72M$ -59.88M--$ -41.88M
Interest Expense
-----
EBIT
$ -80.78M$ -75.80M$ -104.20M$ -89.81M$ -43.82M
EBITDA
$ -92.62M$ -87.64M$ -100.33M$ -90.01M$ -43.72M
Currency in USD

Nuvation Bio Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis